Definitive Healthcare Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Definitive Healthcare Corp. on September 9, 2026. The filing addresses a voluntary disclosure under Regulation FD regarding a Tax Receivable Agreement (TRA) entered into on September 14, 2021, with various TRA Holders including affiliates of Advent International, Spectrum Equity, 22C Capital, and Jason Krantz.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual waiver related to the TRA.
Material Changes and Disclosures
The primary material event disclosed is a waiver by the TRA Holders regarding Early Termination Payments. Key details include:
- Waiver Scope: TRA Holders have irrevocably waived their right to receive an Early Termination Payment under Section 4.1(c) of the TRA.
- Qualifying Change of Control: The waiver applies to any Change of Control where the definitive merger agreement is executed on or prior to December 31, 2026.
- TRA Termination: Upon consummation of a Qualifying Change of Control, the TRA will terminate in accordance with its terms.
- Unaffected Rights: Except for this limited waiver, TRA Holders retain all other rights, including rights to tax benefit payments for taxable years ending prior to, with, or including the consummation of such a transaction.
- Company Role: Definitive Healthcare Corp. is not a party to the Waiver agreement itself.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or new risk factors beyond the specific disclosure of the waiver. The Company explicitly states that the information furnished is not intended to constitute a determination that the information is material or that dissemination is required under Regulation FD.
Investor Verification Checklist
- Verify the exact terms of the Tax Receivable Agreement (TRA) dated September 14, 2021, to understand the baseline obligations.
- Confirm the definition of "Change of Control" and "Early Termination Payment" within the TRA to assess the financial impact of the waiver.
- Monitor for any definitive merger agreements executed by December 31, 2026, which would trigger the waiver and TRA termination.
- Review subsequent filings to determine if the waiver impacts the Company's projected cash outflows related to tax benefit payments.